Actelion Pharmaceuticals’ Tracleer product won US approval in 2001 as the first oral treatment for pulmonary arterial hypertension (PAH), a complex illness that isn’t well known among doctors, and difficult for patients to understand as a result. Tracleer helps patients control the symptoms of PAH, but it has a drawbacks of its own, including slow and gradual results, monthly blood test requirements and myriad side effects. Read the rest of this entry »